## Edgar Filing: Meyers James R - Form 4

| Meyers Jame<br>Form 4  |  |   |     |   |            |   |  |   |   |  |
|--|--|---|-----|---|------------|---|--|---|---|--|
| <b>FORN</b><br>Check th<br>if no long<br>subject to<br>Section 1<br>Form 4 of<br>Form 5<br>obligation<br>may com | obligations<br>may continue.<br>See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section<br>30(h) of the Investment Company Act of 1940 |   |     |   |            |   |  | Number: 3235-0287<br>Expires: January 31<br>Estimated average<br>burden hours per<br>response 0.5 |   |  |
| (Print or Type ]   | Responses)   |   |     |   |            |   |  |   |   |  |
| 1. Name and A<br>Meyers Jam  |  | 2. Issuer Name <b>and</b> Ticker or Trading<br>Symbol<br>CytomX Therapeutics, Inc. [CTMX] |     |   |            | 5. Relationship of Reporting Person(s) to<br>Issuer<br>(Check all applicable)                           |  |   |   |  |
| (Last)<br>C/O CYTO<br>INC., 151 C<br>SUITE 400   | JTICS,   | 3. Date of Earliest Transaction<br>(Month/Day/Year)<br>12/20/2018                         |     |   |            | X_Director10% Owner<br>Officer (give titleOther (specify<br>below) below)                               |  |   |   |  |
|  |  | 4. If Amendment, Date Original<br>Filed(Month/Day/Year)                                   |     |   |            | 6. Individual or Joint/Group Filing(Check<br>Applicable Line)<br>_X_ Form filed by One Reporting Person |  |   |   |  |
| SOUTH SA<br>FRANCISC   | N<br>CO, CA 94080  |   |     |   |            |   | Form filed by Person   | More than One R   | eporting  |  |
| (City)   | (State)  | (Zip)   | Tab | le I - Non-E  | Derivative | Securities A  | cquired, Disposed  | of, or Beneficia  | lly Owned   |  |
| 1.Title of<br>Security<br>(Instr. 3)   |  | action Date 2A. Deemed<br>Day/Year) Execution Date, if<br>any<br>(Month/Day/Year)         |     | TransactionAcquired (A) or<br>Code Disposed of (D)<br>(Instr. 8) (Instr. 3, 4 and 5)<br>(A) |            |   | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I)<br>(Instr. 4)                              | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: Meyers James R - Form 4

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)   | ve Conversion (Month/Day/Year) Exe<br>or Exercise any |            | Execution Date, if | 4.<br>Transactio<br>Code<br>(Instr. 8) | 5. Number o<br>onDerivative<br>Securities<br>Acquired (A<br>or Disposed<br>(D)<br>(Instr. 3, 4,<br>and 5) | Expiration I<br>(Month/Day | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                 | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |  |  |  |
|---|---|------------|--------------------|--|---|----------------------------|--|-----------------|---|--|--|--|
|   |   |            |                    | Code V                                 | (A) (I  | D) Date<br>Exercisable     | Expiration<br>Date   | Title           | Amount<br>or<br>Number<br>of Shares                                 |  |  |  |
| Stock<br>Option<br>(right to<br>buy)  | \$ 14.04  | 12/20/2018 |                    | A                                      | 28,000  | <u>(1)</u>                 | 12/19/2028   | Common<br>Stock | 28,000  |  |  |  |
| Reporting Owners  |   |            |                    |  |   |                            |  |                 |   |  |  |  |
| <b>Reporting Owner Name / Address</b>   |   |            | Relations          | ships                                  |   |                            |  |                 |   |  |  |  |
| topoting of the runner runners  |   |            | Director           | 0% Owner                               | Officer   | Other                      |  |                 |   |  |  |  |
| Meyers James R<br>C/O CYTOMX THERAPEUTICS, INC.<br>151 OYSTER POINT BLVD., SUITE 400<br>SOUTH SAN FRANCISCO, CA 94080 |   |            | 400 <sup>X</sup>   |  |   |                            |  |                 |   |  |  |  |
| Signa   | tures   |            |                    |  |   |                            |  |                 |   |  |  |  |
| /s/ Lloyd Rowland, as Attorney-in-Fact for James R.<br>Meyers   |   |            |                    |  | 12/21/2018  |                            |  |                 |   |  |  |  |

\*\*Signature of Reporting Person

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

1/36th of the shares subject to the option vest on each monthly anniversary measured from December 20, 2018 (the "Vesting

(1) Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.